# Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

> **NCT03466294** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 42 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine and Venetoclax

## Key facts

- **NCT ID:** NCT03466294
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2025-01-29
- **Final completion:** 2025-12-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466294, "Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03466294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*